AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression
Read More
Sep 8, 2026 | News, Regulatory
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression
Read MoreSep 7, 2026 | News, Regulatory
This is the first oral drug treatment for this rare disease in adults
Read MoreSep 4, 2026 | News, Regulatory
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
Read MoreSep 4, 2026 | News, Regulatory
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
Read MoreMS affects nearly three million people worldwide and has three main types
Read MoreThe acquisition is to advance treatments for serious autoimmune and allergic diseases
Read MoreSep 1, 2026 | News, Regulatory
This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer
Read MoreAug 28, 2026 | News, Healthcare
The facility is part of Roche and Genentech’s broader $50bn commitment to US R&D and manufacturing infrastructure
Read MoreAug 27, 2026 | News, Regulatory
67,000 new cases of pancreatic cancer are diagnosed in the US each year
Read MoreAround 112,000 new cases of skin cancer will be diagnosed in the US in 2026
Read MoreAug 25, 2026 | News, Healthcare
This is to expand access to leukaemia treatment in low- and middle-income countries
Read MoreThe company will pay $435m in up front and near-term milestone payments
Read More
